Form 4: Kymera Therapeutics Director Jeffrey Albers Granted 16,000 Stock Options

Kymera Therapeutics, Inc. Director Jeffrey W. Albers was granted 16,000 stock options with an exercise price of $46.47, vesting by June 25, 2026, or the next annual meeting.

Summary

• Jeffrey W. Albers, a Director of Kymera Therapeutics, Inc. (KYMR), was granted 16,000 stock options.
• The transaction date for this grant was June 25, 2025.
• Each stock option has an exercise price of $46.47.
• The options will vest in full upon the earlier of June 25, 2026, or the date of the next annual meeting of Kymera Therapeutics' stockholders.
• The expiration date for these stock options is June 24, 2035.
• Following this transaction, Mr. Albers beneficially owns 16,000 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The grant of stock options to a director is a standard practice that aligns the director's interests with the company's long-term performance, which is generally viewed favorably by investors. It does not indicate any immediate negative or highly unusual circumstances.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance and shareholder value creation of Kymera Therapeutics.
• It serves as a form of incentive compensation, motivating the director to contribute to the company's growth and success.

Negatives

• The value of the options is dependent on the future stock price of Kymera Therapeutics exceeding the exercise price, meaning there is no guaranteed value.
• There is no immediate cash benefit to the director from this grant; value is realized only upon exercise and sale of the underlying shares.

Risks

• The value of the stock options is subject to market volatility and the future performance of Kymera Therapeutics' stock price.
• If the company's stock price does not rise above the exercise price of $46.47, the options may expire worthless.

Future Outlook

The grant of stock options to a director is a forward-looking incentive, designed to align the director's long-term interests with the company's strategic goals and shareholder value creation. The vesting schedule encourages continued service and performance.

Industry Context

The grant of stock options to directors is a common and standard practice in the biotechnology and pharmaceutical industries, as well as across many publicly traded sectors. It is a key component of executive and director compensation packages, aiming to incentivize long-term performance and align leadership interests with those of shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a widely accepted compensation strategy within the biotechnology sector, similar to practices at companies like Moderna, BioNTech, or Regeneron Pharmaceuticals, which frequently use equity-based awards to attract and retain top talent.
• The specific number of options (16,000) and the exercise price ($46.47) would typically be benchmarked against peer companies of similar market capitalization, stage of development, and industry focus to ensure competitive and appropriate compensation.
• The vesting schedule, tied to a specific date or the next annual meeting, is also a common structure designed to ensure continued engagement and long-term commitment from the director.

Related Party Transactions

• The grant of stock options to Jeffrey W. Albers, a Director of Kymera Therapeutics, Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors. This is a standard and disclosed form of executive compensation.

Stakeholder Impact

• Shareholders: The grant aims to align the director's interests with shareholder value creation, potentially leading to better long-term performance.
• Employees: No direct impact mentioned, but a well-compensated and incentivized board can contribute to overall company stability and success.
• Director (Jeffrey W. Albers): Receives equity-based compensation that provides a future financial incentive tied to the company's stock performance.

Next Steps

• The stock options will vest in full upon the earlier of June 25, 2026, or the date of the next annual meeting of Kymera Therapeutics' stockholders.
• Upon vesting, the director will have the right to exercise the options and purchase shares of common stock at the exercise price of $46.47, up until the expiration date of June 24, 2035.

Key Dates

Keywords

Kymera Therapeutics, KYMR, Stock Option, Form 4, Insider Transaction, Director Compensation, Equity Grant, Executive Compensation, SEC Filing